HOPI MEDICAL – Trademark Portfolio
Entity Type: 99
HOPI MEDICAL holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 3 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 6 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ΑAI and BIOGORA.
18 rue du Général de Gaulle
F-67560 ROSHEIM
Showing of trademarks Trademarks
Trademark Classifications
HOPI MEDICAL's trademark portfolio spans 6 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does HOPI MEDICAL have?
HOPI MEDICAL has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned.
What trademark classes does HOPI MEDICAL file in?
HOPI MEDICAL files trademarks across 6 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are HOPI MEDICAL's most well-known trademarks?
HOPI MEDICAL's registered trademark portfolio includes well-known marks such as ΑAI and BIOGORA. These are among 2 currently registered trademarks in the portfolio.
What is HOPI MEDICAL's trademark registration success rate?
HOPI MEDICAL has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.